IGC (IGC Pharma) Tariff Resilience Score: 7/10 (As of Jun. 29, 2026)


IGC IGC Pharma Inc IGC
29 GF Score
Price $0.27
GF Value $0.24
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is IGC Pharma Tariff Resilience Score?

IGC Pharma IGC +3.04% 29 Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus rates IGC with a GF Score™ of 29/100 and a GF Value™ of $0.24 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 1,375 Biotechnology companies, IGC Pharma ranks better than 90.4% on this metric.

IGC Pharma has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

IGC Pharma has IGC Pharma Inc has moderate tariff exposure. While pharmaceuticals are often exempt, the company relies on global supply chains for raw materials, which could face tariff impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes IGC Pharma might have Highly Resilient.

IGC Pharma  (AMEX:IGC) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

IGC Pharma Tariff Resilience Score Related Terms

IGC vs SER, NRSN, PVCT: Tariff Resilience Score Comparison

For the Biotechnology subindustry, IGC Pharma's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

IGC Pharma Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, IGC Pharma's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where IGC Pharma's Tariff Resilience Score falls into.


IGC
29GF Score
IGC Pharma Inc IGC
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
IGC Pharma (IGC) has a Tariff Resilience Score of 7 as of Jun. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, IGC Pharma ranks #132 out of 1375 companies in the Biotechnology industry, placing it in the top 9.6%.
Is IGC Pharma's Tariff Resilience Score too high?
IGC Pharma's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. IGC Pharma's value of 7 is 75% above this industry median. Based on the distribution chart, IGC Pharma ranks #132 out of 1375 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, IGC Pharma has a GF Score™ of 29/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does IGC Pharma's Tariff Resilience Score compare to SER and NRSN?
According to the Biotechnology industry distribution chart, IGC Pharma ranks #132 out of 1375 companies for Tariff Resilience Score. This places IGC Pharma in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. IGC Pharma's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,375 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. IGC Pharma's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. IGC Pharma's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IGC Pharma stock overvalued right now?
Based on GuruFocus' analysis, IGC Pharma (IGC) is currently considered Modestly Overvalued. The stock's GF Value™ is $0.24, compared to a current price of $0.27 — trading 12.9% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. IGC Pharma's overall GF Score™ is 29/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For IGC Pharma (IGC), the current Tariff Resilience Score is 7 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is IGC Pharma (IGC) Overvalued in 2026?

Based on GuruFocus' analysis, IGC Pharma stock appears to be overvalued. The current stock price of $0.27 is trading 12.9% above its estimated GF Value™ of $0.24. GuruFocus considers IGC Pharma to be Modestly Overvalued.

Key valuation signals for IGC:

  • Tariff Resilience Score: 7
  • GF Value™: $0.24 vs. price of $0.27 (12.9% above fair value)
  • GF Score™: 29/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1375)

No single metric tells the full story. See the IGC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

IGC Pharma Business Description

Other Exchanges IGS1:Germany
Address 10224 Falls Road, Potomac, MD, USA, 20854
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer's disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer's disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer's cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer's disease, such as plaques or tangles.
29GF Score

Get the complete analysis for IGC

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.27
Price
$0.24
GF Value